A groundbreaking at-home test has the potential to transform the way dementia is diagnosed, offering a glimpse into a person’s likelihood of developing Alzheimer’s disease.
Researchers have developed a finger-prick blood test and an online brain assessment that could enable widespread screening for the most prevalent form of dementia, identifying individuals exhibiting early signs of memory and cognitive issues. This home testing method could help pinpoint those at highest risk, allowing them to receive prioritized monitoring, diagnosis, and necessary support.
Professor Anne Corbett, leading the study at the University of Exeter Medical School, highlighted the significance of this approach in screening individuals for dementia risk without the need for traditional clinical evaluations. Identifying those at highest risk early on could facilitate timely interventions, providing tailored support and treatment to those in need.
In the UK, nearly one million people are living with dementia, with Alzheimer’s disease being the leading cause, responsible for 60% to 80% of cases. With potential disease-modifying treatments undergoing clinical trials, early diagnosis becomes crucial for effective intervention. However, most dementia cases in the UK are diagnosed late or not at all, emphasizing the importance of innovative diagnostic tools.
Published in the journal Nature Communications, a recent study involved 174 participants who self-administered an at-home test and returned it to the research team. The test examined blood biomarkers, p-tau217 and GFAP, associated with Alzheimer’s disease and overall brain decline. Participants also engaged in online cognitive assessments.
Dr. Sheona Scales, director at Alzheimer’s Research UK, hailed the potential of finger-prick blood tests in revolutionizing dementia diagnosis, offering a cost-effective and scalable method to identify individuals at higher risk of Alzheimer’s disease who may require further evaluation.
The study revealed that the blood test, when combined with computerized cognitive assessments, can effectively assess an individual’s risk of developing Alzheimer’s disease.
Professor Clive Ballard from the University of Exeter Medical School, involved in the research, stressed the need for innovative approaches to reach individuals in the community who might not otherwise receive timely diagnosis or support for cognitive decline.
Dr. Scales emphasized the importance of self-administered tests as an initial step in the diagnostic process, providing reassurance to some while expediting follow-up assessments for others. The convenience and remote accessibility of these tests could enhance assessment accessibility for individuals facing practical barriers to clinic visits.
To further validate the effectiveness of this tool in routine healthcare settings, larger and more diverse studies are required.
Professor Ballard encouraged individuals over 40 to participate in the online Protect study, engaging more than 30,000 UK adults in regular cognitive assessments to monitor memory, attention, and decision-making skills.
